Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans.
Journal
The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
received:
27
04
2022
revised:
30
05
2022
accepted:
17
06
2022
entrez:
1
7
2022
pubmed:
2
7
2022
medline:
8
7
2022
Statut:
ppublish
Résumé
The single-dose Ad.26.COV.2 (Janssen) vaccine elicits lower levels of neutralizing antibodies and shows more limited efficacy in protection against infection than either of the two available mRNA vaccines. In addition, Ad.26.COV.2 has been less effective in protection against severe disease during the Omicron surge. Here, we examined the memory B cell response to single-dose Ad.26.COV.2 vaccination. Compared with mRNA vaccines, Ad.26.COV.2 recipients had significantly lower numbers of RBD-specific memory B cells 1.5 or 6 mo after vaccination. Despite the lower numbers, the overall quality of the memory B cell responses appears to be similar, such that memory antibodies elicited by both vaccine types show comparable neutralizing potency against SARS-CoV-2 Wuhan-Hu-1, Delta, and Omicron BA.1 variants. The data help explain why boosting Ad.26.COV.2 vaccine recipients with mRNA vaccines is effective and why the Ad26.COV2.S vaccine can maintain some protective efficacy against severe disease during the Omicron surge.
Identifiants
pubmed: 35776090
pii: 213320
doi: 10.1084/jem.20220732
pmc: PMC9253517
pii:
doi:
Substances chimiques
Ad26COVS1
JT2NS6183B
Antibodies, Neutralizing
0
Vaccines
0
mRNA Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI078788
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001866
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI165075
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI138938
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI064003
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI111825
Pays : United States
Organisme : Shapiro-Silverberg Fund for the Advancement of Translational Research
Informations de copyright
© 2022 Cho et al.
Références
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Front Immunol. 2022 Jan 12;12:825813
pubmed: 35095929
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
N Engl J Med. 2022 Mar 3;386(9):847-860
pubmed: 35139271
N Engl J Med. 2022 Mar 10;386(10):933-941
pubmed: 35020982
N Engl J Med. 2022 Jan 13;386(2):116-127
pubmed: 34942067
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Annu Rev Med. 2022 Jan 27;73:1-16
pubmed: 34428080
N Engl J Med. 2021 Sep 2;385(10):951-953
pubmed: 34260834
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Science. 2020 Aug 28;369(6507):1119-1123
pubmed: 32661058
J Exp Med. 2006 Oct 30;203(11):2419-24
pubmed: 17030950
Elife. 2020 Oct 28;9:
pubmed: 33112236
MMWR Morb Mortal Wkly Rep. 2022 Apr 01;71(13):495-502
pubmed: 35358170
Immunity. 2022 Jun 14;55(6):998-1012.e8
pubmed: 35447092
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
Nat Rev Immunol. 2021 Jun;21(6):382-393
pubmed: 33875867
Nature. 2008 May 29;453(7195):667-71
pubmed: 18449194
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Annu Rev Immunol. 2022 Apr 26;40:413-442
pubmed: 35113731
Nature. 2021 Dec;600(7889):517-522
pubmed: 34619745
Trends Immunol. 2021 Apr;42(4):336-349
pubmed: 33663954
Vaccines (Basel). 2022 Sep 03;10(9):
pubmed: 36146536
Sci Immunol. 2022 Mar 25;7(69):eabo2202
pubmed: 35113647
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Cell. 2021 Jul 22;184(15):3936-3948.e10
pubmed: 34192529
N Engl J Med. 2022 Jun 23;386(25):2433-2435
pubmed: 35613039
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
N Engl J Med. 2022 Mar 17;386(11):1046-1057
pubmed: 35081293
JAMA Netw Open. 2022 Mar 1;5(3):e220868
pubmed: 35234883
Nat Rev Immunol. 2021 Apr;21(4):209-220
pubmed: 33024284
Nature. 2019 Feb;566(7744):398-402
pubmed: 30760926
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
Cell. 2020 Jan 9;180(1):92-106.e11
pubmed: 31866068
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
N Engl J Med. 2021 Nov 18;385(21):2010-2012
pubmed: 34648703
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
N Engl J Med. 2022 Mar 10;386(10):951-963
pubmed: 35045226
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Cell. 2020 Nov 25;183(5):1298-1311.e11
pubmed: 33125897
Bioinformatics. 2015 Oct 15;31(20):3356-8
pubmed: 26069265
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343
pubmed: 34555004
Cell. 2022 Jul 7;185(14):2434-2451.e17
pubmed: 35764089
Nature. 2022 Mar;603(7901):493-496
pubmed: 35102312
N Engl J Med. 2007 Nov 8;357(19):1903-15
pubmed: 17989383
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Front Immunol. 2019 Oct 09;10:2365
pubmed: 31649674
N Engl J Med. 2021 Nov 11;385(20):e70
pubmed: 34614319
Cell Rep. 2022 Feb 15;38(7):110368
pubmed: 35123652
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Nature. 2021 Aug;596(7871):268-272
pubmed: 34107529
Front Immunol. 2018 Aug 13;9:1858
pubmed: 30150988
PLoS One. 2016 Aug 11;11(8):e0160853
pubmed: 27513338
N Engl J Med. 2022 Jan 27;386(4):340-350
pubmed: 35021002
Lancet. 2022 Mar 19;399(10330):1141-1153
pubmed: 35305740
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
N Engl J Med. 2022 Jun 9;386(23):2243-2245
pubmed: 35507482
Immunity. 2016 Jan 19;44(1):116-130
pubmed: 26795247
Nature. 2022 Jul;607(7917):128-134
pubmed: 35447027
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Cell. 2022 May 26;185(11):1875-1887.e8
pubmed: 35523182